Tevogen Bio Regains Nasdaq Compliance, Removing Delisting Risk
summarizeSummary
Tevogen Bio Holdings Inc. announced it has formally regained compliance with Nasdaq's minimum bid price requirement, removing the risk of delisting. The company had previously received a notification in September 2025 for failing to maintain a $1.00 minimum bid price. This positive development ensures TVGN's continued listing on The Nasdaq Global Market, which is crucial for investor confidence and liquidity, particularly for a small-cap biotech firm. This procedural update follows recent positive news regarding its TVGN 489 program for Long COVID and advancements in its PredicTcell™ Beta AI model, which likely contributed to the stock price recovery above the $1.00 threshold.
At the time of this announcement, TVGN was trading at $5.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $4.89 to $75.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.